Esophageal tolerance to high-dose stereotactic ablative radiotherapy
Diseases of the Esophagus, 04/25/2012
Abelson JA et al. – The authors report a dosimetric analysis of incidental dose to the esophagus from stereotactic ablative radiotherapy (SABR). High–dose hypofractionated radiotherapy led to a number of high–grade esophageal adverse events, suggesting that conservative parameters to protect the esophagus are necessary when SABR is used, especially in the setting of chemotherapy or prior radiotherapy.